Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | GLS | O94925 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.42 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL461209 | 1.00 | CASP3 (0.53) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL4468251 | 0.87 | CASP3 (0.60) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL8950475 | 0.87 | CASP3 (0.60) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL4476083 | 0.87 | CASP3 (0.60) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL15485550 | 0.84 | CYP1B1 (0.57) | ALDH1A1RCE1 | |
| SCHEMBL29443002 | 0.82 | CASP3 (0.51) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL30423183 | 0.82 | CASP3 (0.51) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL4581604 | 0.82 | CASP3 (0.51) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL4581609 | 0.82 | CASP3 (0.51) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL5839893 | 0.82 | CASP3 (0.51) | CASP3CA12CA9GLSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080160594-A1 | Methods of Light Activated Release of Ligands from Endosomes | INVITROGEN CORPORATION (US) | 2008-07-03 | — | — | US | disclosed |
| EP-0731807-B1 | N-2 SUBSTITUTED PURINES | ISIS PHARMACEUTICALS INC (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030031655-A1 | Methods of light activated release of ligands from endosomes | SEQUITUR, INC. (US) | 2003-02-13 | — | — | US | disclosed |
| WO-2002062989-A2 | METHODS OF LIGHT ACTIVATED RELEASE 0F LIGANDS FROM ENDOSOMES | SEQUITUR, INC. (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-0635023-B1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2002-02-06 | — | — | EP | disclosed |
| US-6166199-A | N-2 substituted purines | ISIS PHARMACEUTICALS, INC (US) | 2000-12-26 | — | — | US | disclosed |
| US-6127124-A | MONITORING THE STABILTY OF AN OLIGOMER TO ENZYMATIC DIGESTION; DIGESTING OLIGONUCLEOTIDE, SUBJECTING DIGESTION MIXTURE TO ELECTROPHORESIS, DETECTING DIGESTION PRODUCTS BY FLUORESENCE | ISIS PHARMACEUTICALS, INC. (US) | 2000-10-03 | — | — | US | disclosed |
| US-5808027-A | ANTISENSE AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1998-09-15 | — | — | US | disclosed |
| EP-0742790-A4 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS INC (US) | 1998-05-06 | — | — | EP | disclosed |
| US-5719271-A | HYBRIDS; GENETIC ENGINEERING | ISIS PHARMACEUTICALS, INC. (US) | 1998-02-17 | — | — | US | disclosed |
| US-5587469-A | USEFUL AS ?ANTISENSE AGENTS? THAT ARE CAPABLE OF SPECIFIC HYBRIDIZATION WITH A NUCLEOTIDE SEQUENCE OF AN RNA | ISIS PHARMACEUTICALS, INC. (US) | 1996-12-24 | — | — | US | disclosed |
| EP-0742790-A1 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS, INC. (US) | 1996-11-20 | — | — | EP | disclosed |
| EP-0731807-A1 | N-2 SUBSTITUTED PURINES | ISIS PHARMACEUTICALS, INC. (US) | 1996-09-18 | — | — | EP | disclosed |
| US-5543507-A | BONDING STRANDS OR ONE STRAND AT DIFFERENT SITES; RNA MIMICS FIXED IN SPATIAL CONFORMATION; NUCLEASE RESISTANT MIMICS OF BINDING RECEPTORS FOR NUCLEIC ACID-BINDING PROTEINS; 5-LIPOXYGENASE INHIBITORS; DIAGNOSIS; ANALYZING | ISIS PHARMACEUTICALS, INC. (US) | 1996-08-06 | — | — | US | disclosed |
| EP-0635023-A4 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES. | ISIS PHARMACEUTICALS INC (US) | 1996-03-20 | — | — | EP | disclosed |
| US-5459255-A | For incorporation into oligonucleotides, cleaving RNA site specifically | ISIS PHARMACEUTICALS, INC. (US) | 1995-10-17 | — | — | US | disclosed |
| WO-1995021184-A1 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS, INC. (US) | 1995-08-10 | — | — | WO | disclosed |
| WO-1995014707-A1 | N-2 SUBSTITUTED PURINES | ISIS PHARMACEUTICALS, INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| EP-0635023-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-01-25 | — | — | EP | disclosed |
| WO-1993018052-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030031655-A1 | Methods of light activated release of ligands from endosomes | LAMP2, PLAUR, CLTB | CASP3 1948/4885CA12 3270/4885CA9 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.